BACKGROUND: The cathelicidin family of antimicrobial peptides is an integral component of the innate immune response that exhibits activity against bacterial, fungal, and viral pathogens. Eczema herpeticum (ADEH) develops in a subset of patients with atopic dermatitis (AD) because of disseminated infection with herpes simplex virus (HSV). OBJECTIVE: This study investigated the potential role of cathelicidins in host susceptibility to HSV infection. METHODS: Glycoprotein D was measured by means of real-time RT-PCR as a marker of HSV replication in skin biopsy specimens and human keratinocyte cultures. Cathelicidin expression was evaluated in skin biopsy specimens from patients with AD (n = 10) without a history of HSV skin infection and from patients with ADEH (n = 10). RESULTS: The cathelicidin peptide LL-37 (human cathelicidin) exhibited activity against HSV in an antiviral assay, with significant killing (P < .001) within the physiologic range. The importance of cathelicidins in antiviral skin host defense was confirmed by the observation of higher levels of HSV-2 replication in cathelicidin-deficient (Cnlp-/-) mouse skin (2.6 +/- 0.5 pg HSV/pg GAPDH, P < .05) compared with that seen in skin from their wild-type counterparts (0.9 +/- 0.3). Skin from patients with ADEH exhibited significantly (P < .05) lower levels of cathelicidin protein expression than skin from patients with AD. We also found a significant inverse correlation between cathelicidin expression and serum IgE levels (r2 = 0.46, P < .05) in patients with AD and patients with ADEH. CONCLUSION: This study demonstrates that the cathelicidin peptide LL-37 possesses antiviral activity against HSV and demonstrates the importance of variable skin expression of cathelicidins in controlling susceptibility to ADEH. Additionally, serum IgE levels might be a surrogate marker for innate immune function and serve as a biomarker for which patients with AD are susceptible to ADEH. CLINICAL IMPLICATIONS: A deficiency of LL-37 might render patients with AD susceptible to ADEH. Therefore increasing production of skin LL-37 might prevent herpes infection in patients with AD.
BACKGROUND: The cathelicidin family of antimicrobial peptides is an integral component of the innate immune response that exhibits activity against bacterial, fungal, and viral pathogens. Eczema herpeticum (ADEH) develops in a subset of patients with atopic dermatitis (AD) because of disseminated infection with herpes simplex virus (HSV). OBJECTIVE: This study investigated the potential role of cathelicidins in host susceptibility to HSV infection. METHODS: Glycoprotein D was measured by means of real-time RT-PCR as a marker of HSV replication in skin biopsy specimens and human keratinocyte cultures. Cathelicidin expression was evaluated in skin biopsy specimens from patients with AD (n = 10) without a history of HSV skin infection and from patients with ADEH (n = 10). RESULTS: The cathelicidin peptide LL-37 (human cathelicidin) exhibited activity against HSV in an antiviral assay, with significant killing (P < .001) within the physiologic range. The importance of cathelicidins in antiviral skin host defense was confirmed by the observation of higher levels of HSV-2 replication in cathelicidin-deficient (Cnlp-/-) mouse skin (2.6 +/- 0.5 pg HSV/pg GAPDH, P < .05) compared with that seen in skin from their wild-type counterparts (0.9 +/- 0.3). Skin from patients with ADEH exhibited significantly (P < .05) lower levels of cathelicidin protein expression than skin from patients with AD. We also found a significant inverse correlation between cathelicidin expression and serum IgE levels (r2 = 0.46, P < .05) in patients with AD and patients with ADEH. CONCLUSION: This study demonstrates that the cathelicidin peptide LL-37 possesses antiviral activity against HSV and demonstrates the importance of variable skin expression of cathelicidins in controlling susceptibility to ADEH. Additionally, serum IgE levels might be a surrogate marker for innate immune function and serve as a biomarker for which patients with AD are susceptible to ADEH. CLINICAL IMPLICATIONS: A deficiency of LL-37 might render patients with AD susceptible to ADEH. Therefore increasing production of skin LL-37 might prevent herpes infection in patients with AD.
Authors: M Frohm; B Agerberth; G Ahangari; M Stâhle-Bäckdahl; S Lidén; H Wigzell; G H Gudmundsson Journal: J Biol Chem Date: 1997-06-13 Impact factor: 5.157
Authors: Peck Y Ong; Takaaki Ohtake; Corinne Brandt; Ian Strickland; Mark Boguniewicz; Tomas Ganz; Richard L Gallo; Donald Y M Leung Journal: N Engl J Med Date: 2002-10-10 Impact factor: 91.245
Authors: Y Jerold Gordon; Ling C Huang; Eric G Romanowski; Kathleen A Yates; Rita J Proske; Alison M McDermott Journal: Curr Eye Res Date: 2005-05 Impact factor: 2.424
Authors: Donald Y M Leung; Mark Boguniewicz; Michael D Howell; Ichiro Nomura; Qutayba A Hamid Journal: J Clin Invest Date: 2004-03 Impact factor: 14.808
Authors: Zhenping Wang; Yuping Lai; Jamie J Bernard; Daniel T Macleod; Anna L Cogen; Bernard Moss; Anna Di Nardo Journal: J Immunol Date: 2011-12-02 Impact factor: 5.422
Authors: Amy D Proal; Paul J Albert; Greg P Blaney; Inge A Lindseth; Chris Benediktsson; Trevor G Marshall Journal: Cell Mol Immunol Date: 2011-01-31 Impact factor: 11.530
Authors: Shauna Schroeder; Zachary D Robinson; Joanne C Masterson; Lindsay Hosford; Wendy Moore; Zhaoxing Pan; Rachel Harris; Rhonda F Souza; Stuart Jon Spechler; Sophie A Fillon; Glenn T Furuta Journal: Pediatr Res Date: 2013-02-05 Impact factor: 3.756
Authors: Pei-Song Gao; Kenichi Shimizu; Audrey V Grant; Nicholas Rafaels; Lin-Fu Zhou; Sherry A Hudson; Satoshi Konno; Nives Zimmermann; Maria I Araujo; Eduardo V Ponte; Alvaro A Cruz; Masaharu Nishimura; Song-Nan Su; Nobuyuki Hizawa; Terry H Beaty; Rasika A Mathias; Marc E Rothenberg; Kathleen C Barnes; Bruce S Bochner Journal: Eur J Hum Genet Date: 2010-01-20 Impact factor: 4.246
Authors: Emma Guttman-Yassky; Michelle A Lowes; Judilyn Fuentes-Duculan; Lisa C Zaba; Irma Cardinale; Kristine E Nograles; Artemis Khatcherian; Inna Novitskaya; John A Carucci; Reuven Bergman; James G Krueger Journal: J Immunol Date: 2008-11-15 Impact factor: 5.422